BIBLIOGRAPHIE

1. Bayati, A. et al., 2021, **"SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis"**, J Biol Chem. doi: 10.1016/j.jbc.2021.100306.

2. Cantuti-Castelvetri, L. et al., 2020, **"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity"**, Science. doi: 10.1126/science.abd2985.

3. Hoffmann, M. et al., 2020, **"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"**, Cell. doi: 10.1016/j.cell.2020.02.052.

4. Lempp, F.A. et al., 2021, **"Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies"**, Nature volume 598, pages 342–347.

5. Kalra, K. S. & Kandimalla, R., 2021, **"Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection", *Signal Transduction and Targeted Therapy* volume 6**, Article number: 39

6. Diamond, M. S. and Kanneganti, T.-D., 2022, **"Innate immunity: the first line of defense against SARS-CoV-2"**, *Nature Immunology* **volume 23**, pages 165–176

7. Totura, A. L. et al., 2015, **"Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection"**, mBio. doi: 10.1128/mBio.00638-15.

8. Zhang, Q. et al., 2020, **"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19"**, Science. doi: 10.1126/science.abd4570.

9. Borghi, M.O. et al., 2020, **"Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome"**, Front Immunol. doi: 10.3389/fimmu.2020.584241.

10. Hurst, J. et al., 2009, **"TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells"**, Immunobiology. doi: 10.1016/j.imbio.2008.12.003.

11. Seneff, S. et al., 2022, **"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs"**, Food Chem Toxicol. doi: 10.1016/j.fct.2022.113008.

12. Andreakos, E. et al., 2022, **"A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection"**, *Nature Immunology* **volume 23**, pages 159–164

13. Troya, J. et al., 2021, **"Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain"**, *Journal of Clinical Immunology* **volume 41**, pages 914–922

14. Liu, G. et al., 2021, **"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity"**, *Nature Microbiology* **volume 6**, pages 467–478

15. Lei, X. et al., 2020, **"Activation and evasion of type I interferon responses by SARS-CoV-2"**, *Nature Communications* **volume 11**, Article number: 3810

16. Colmenero, I. et al., 2020, **"SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases."** Br. J. Dermatol 183, 729–737

17. Chou, J. et al., 2022, **"Immunology of SARS-CoV-2 infection in children"**, Nature Immunology VOL 23

18. Petter Brodin et al., 2021, **"Studying severe long COVID to understand post-infectious disorders beyond COVID-19"**, *Nature Medicine*

19. Zhang, Y. et al., 2021, **"The ORF8 Protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-1"**, PNAS, https://doi.org/10.1073/pnas.2024202118

20. Vivier, E. et al., 2011, **"Innate or Adaptive Immunity? The Example of Natural Killer Cells"**, Science. doi: 10.1126/science.1198687

21. Jacob, J. et al., 1991, **"In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations"**, J Exp Med. doi: 10.1084/jem.173.5.1165.

22. Amélie Bonaud, thèse 2015, **"Maturation finale des lymphocytes B : de la commutation de classe aux conséquences pathologiques de la production d'immunoglobulines anormales"**

23. Kim, S.D. et al., 2020, **"Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies"**, Front. Immunol. https://doi.org/10.3389/fimmu.2020.571481

24. Hasan, A. et al., 2021, **"Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches"**, Immunotargets Ther. 2021; 10: 63–85. doi: 10.2147/ITT.S280706

25. Cerutti, A. et Rescigno, M., 2008, **"The biology of intestinal immunoglobulin A responses"**, Immunity. doi: 10.1016/j.immuni.2008.05.001.

26. Wahl, S.M. et al., 1990, **"Macrophage production of TGF-beta and regulation by TGF-beta"**, Ann N Y Acad Sci. 1990;593:188-96. doi: 10.1111/j.1749-6632.1990.tb16111.x.

27. Davis, S. K. et al., 2020, **"Serum IgA Fc effector functions in infectious disease and cancer"**, Immunology & Cell Biology2020;98: 276–286

28. Paul Moss, 2022, **"The T cell immune response against SARS-CoV-2"**, Nature Immunology volume 23, pages 186–193

29. Tan, L. et al., 2020, **"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study"**, *Signal Transduction and Targeted Therapy* **volume 5**, Article number: 61

30. Lucas, C. et al., 2020, **"Longitudinal analyses reveal immunological misfiring in severe COVID-19"**, Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y.

31. Helal, M.A. et al., 2020, **"Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia"**, https://doi.org/10.1080/07391102.2020.1822208

32. Emadeldin H.E. Konozy, 2021, **"SARS-CoV-2 and Plasmodium falciparum are probably adopting Analogous strategy to invade erythrocytes"**, doi: 10.1016/j.jiph.2021.04.014

33. Ulrich, H. & Pillat, M.M., 2020, **"CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement"**, Stem Cell Rev Rep. doi: 10.1007/s12015-020-09976-7.

34. Hernán F. Peñaloza et al., 2021, **"Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease"**, https://doi.org/10.1371/journal.ppat.1009850

35. Zhang, Z. et al., 2021, **"SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination"**, Cell Death Differ. doi: 10.1038/s41418-021-00782-3.

36. André, S. et al., 2022, **"T cell apoptosis characterizes severe Covid-19 disease"**, *Cell Death & Differentiation*, https://www.nature.com/articles/s41418-022-00936-x

37. Martonik, D. et al., 2021, **"The Role of Th17 Response in COVID-19"**, Cells. 2021 Jun 19;10(6):1550. doi: 10.3390/cells10061550.

38. Eren Cagan et al., 2022, **"The Age-Dependent Role of Th22, Tc22, and Tc17Cells in the Severity of Pneumonia in COVID-19 Immunopathogenesis"**, VIRAL IMMUNOLOGY Volume 00, Number 00, 2022 Mary Ann Liebert, Inc.Pp. 1–10 DOI: 10.1089/vim.2021.0132

39. McGeachy, M. J. et al., 2019, **"The IL-17 Family of Cytokines in Health and Disease"**, Immunity. 2019 Apr 16;50(4):892-906. doi: 10.1016/j.immuni.2019.03.021

40. Sakaguchi, R. et al., 2015, **"Innate-like function of memory T h 17 cells for enhancing endotoxin-induced acute lung inflammation through IL-22"**, International Immunology, Volume 28, Issue 5, May 2016, Pages 233–243, https://doi.org/10.1093/intimm/dxv070

41. Zheng, J. et al., 2022, **"Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects"**, *Cellular & Molecular Immunology* **volume 19**, pages 150–157 (2022)

42. Kaplan, M.H. et al., 2015, **"The Development and in vivo function of TH9 cells"**, Nat Rev Immunol. 2015 May; 15(5): 295–307. doi: 10.1038/nri3824

43. Yu, X. et al., 2017, **"The Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar Macrophages"**, Immunity. 2017 Nov 21;47(5):903-912.e4. doi: 10.1016/j.immuni.2017.10.007. Epub 2017 Nov 7

44. Schneider, C. et al., 2014, **"Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages"**, *Nature Immunology* **volume 15**, pages 1026–1037

45. Nobs & Kopf, 2018, **"PPAR-γ in innate and adaptive lung immunity"**, J Leukoc Biol. 2018 Oct;104(4):737-741. doi: 10.1002/JLB.3MR0118-034R.

46. Heming, M. et al., 2018, **"Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids"**, Front Immunol. 2018 May 8;9:893. doi: 10.3389/fimmu.2018.00893.

47. Micossé C. et al., 2019, **"Human "T_H9" cells are a subpopulation of PPAR-γ + T_H2 cells"**, Sci Immunol. 2019 Jan 18;4(31):eaat5943. doi: 10.1126/sciimmunol.aat5943.

48. Moretti, S. et al., 2017, **"A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis"**, Nat Commun. 2017 Jan 16;8:14017. doi: 10.1038/ncomms14017.

49. Willard, M. A. M. et al., 2012, **"Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33"**, *J Exp Med* (2012) 209 (8): 1505–1517. https://doi.org/10.1084/jem.20112691

50. Kim, C.W. et al., 2019, **"Exogenous Interleukin-33 Contributes to Protective Immunity via Cytotoxic T-Cell Priming against Mucosal Influenza Viral Infection"**, Viruses. 2019 Sep 10;11(9):840. doi: 10.3390/v11090840.

51. Morrison, C. B. et al., 2022, **"SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13"**, https://doi.org/10.1073/pnas.2119680119

52. Chung-Jen Wang et al., 2022, **"Asthma and COVID-19 Associations: Focus on IgE-Related Immune Pathology"**, *Life* **2022**, *12*(2), 153, https://doi.org/10.3390/life12020153

53. Tan, C. et al., 2022, **"Hypersensitivity may be involved in severe COVID-19"**, Clin Exp Allergy. 2022 Feb;52(2):324-333. doi: 10.1111/cea.14023. Epub 2021 Oct 9.

54. Haimanot Wasse, et al., 2012, **"Impact of Mast Cell Chymase on Renal Disease Progression"**, Curr Hypertens Rev. 2012 Feb 1; 8(1): 15–23, doi: 10.2174/157340212800505007

55. El-Arif, G. et al., 2021, **"The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19"**, Molecules 2021, 26(22), 6945; https://doi.org/10.3390/molecules26226945

56. Valent, P., 2013, **"Mast cell activation syndromes: definition and classification"**, EAACI, https://doi.org/10.1111/all.12126

57. Frieri, M., 2018, **"Mast Cell Activation Syndrome"**, *Clinical Reviews in Allergy & Immunology* **volume 54**, pages 353–365

58. Mittal, A. et al., 2019, **"Mast Cell Neural Interactions in Health and Disease"**, Front. Cell. Neurosci., https://doi.org/10.3389/fncel.2019.00110

59. Hatziantoniou, S. et al., 2021, **"Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study"**, Vaccine. doi: 10.1016/j.vaccine.2021.03.073.

60. Wilhelm, C. et al., 2012, **"Interleukin 9 fate reporter reveals induction of innate IL-9 response in lung inflammation",** Nat immunol, doi: 10.1038/ni.2133

61. Klemm, T. et al., 2020, **"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2"**, The EMBO Journal, https://doi.org/10.15252/embj.2020106275

62. Acosta-Ampudia, Y. et al., 2022, **"Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome"** J Infect Dis. 2022 Jan 25;jiac017. doi: 10.1093/infdis/jiac017.

63. Chen, J. et al., 2019, **"T Helper 9 Cells: A New Player in Immune-Related Diseases"**, DNA Cell Biol. 2019 Oct 1; 38(10): 1040–1047. doi: 10.1089/dna.2019.4729

64. Li, S. et al., 2014, **"Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments"**, Mediators Inflamm. 2014; 2014: 740947, doi: 10.1155/2014/740947

65. He, Y. et al., 2021, **"Immunopathobiology and therapeutic targets related to cytokines in liver diseases"**, Cellular & Molecular Immunology volume 18, pages 18–37, https://doi.org/10.1038/s41423-020-00580-w

66. Salazar, Y. et al., 2020, **"Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer"**, The Journal of Clinical Investigation, 10.1172/JCI124037

67. Karpisheh, V. et al., 2022, **"The role of Th17 cells in the pathogenesis and treatment of breast cancer"**, Cancer Cell International BMC, https://doi.org/10.1186/s12935-022-02528-8

68. Hoffmann, M. et Pöhlmann, S., 2021, **"Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1"**, *Cell* Res. 32, 1–2 (2022). https://doi.org/10.1038/s41422-021-00603-9

69. Gu, Y. et al., 2022, **"Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2"**, Cell Res. 32(1):24-37. doi: 10.1038/s41422-021-00595-6.

70. Barin, B. et al., 2022, **"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study"**, THE LANCET Microbe, DOI: https://doi.org/10.1016/S2666-5247(21)00305-0

71. Shen, X.-R. et al., 2022, **"ACE2-independent infection of T lymphocytes by SARS-CoV-2"**, Signal Transduction and Targeted Therapy, volume 7, Article number: 83, https://doi.org/10.1038/s41392-022-00919-x

72. Tardif, M.R. & Tremblay, M.J., 2005, **"LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1"**, J Virol 79(21):13714-24. doi: 10.1128/JVI.79.21.13714-13724.2005.